Yüklüyor......
Inclisiran: First Approval
Inclisiran (Leqvio(®); Novartis) is a first-in-class, cholesterol-lowering small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine carbohydrates (GalNAc). Inclisiran received its first approval in December 2020 in the EU for use in adults with primary hypercholesterolaemia (he...
Kaydedildi:
| Yayımlandı: | Drugs |
|---|---|
| Yazar: | |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Springer International Publishing
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7900795/ https://ncbi.nlm.nih.gov/pubmed/33620677 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-021-01473-6 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|